Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK2 | P49760 | 15/20 | 0.62 |
| ▸ | DYRK1A | Q13627 | 15/20 | 0.62 |
| ▸ | WNT1 | P04628 | 3/20 | 0.57 |
| ▸ | CLK3 | P49761 | 14/20 | 0.57 |
| ▸ | PRKACA | P17612 | 2/20 | 0.49 |
| ▸ | PRKACG | P22612 | 2/20 | 0.49 |
| ▸ | PRKACB | P22694 | 2/20 | 0.49 |
| ▸ | AKT1 | P31749 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20437293 | 0.92 | CLK2 (0.64) | CLK2DYRK1AWNT1CLK3PRKACA | |
| SCHEMBL20423009 | 0.92 | CLK2 (0.64) | CLK2DYRK1AWNT1CLK3PRKACA | |
| SCHEMBL18478228 | 0.91 | CLK2 (0.54) | CLK2DYRK1AWNT1CLK3 | |
| SCHEMBL18444020 | 0.91 | WNT1 (0.64) | CLK2DYRK1AWNT1CLK3PRKACA | |
| SCHEMBL20422994 | 0.91 | CLK2 (0.69) | CLK2DYRK1AWNT1CLK3PRKACA | |
| SCHEMBL20422822 | 0.90 | CLK2 (0.73) | CLK2DYRK1AWNT1CLK3PRKACA | |
| SCHEMBL18478232 | 0.90 | CLK2 (0.52) | CLK2DYRK1AWNT1CLK3 | |
| SCHEMBL18446516 | 0.90 | WNT1 (0.58) | CLK2DYRK1AWNT1CLK3PRKACA | |
| SCHEMBL20455183 | 0.90 | CLK2 (0.57) | CLK2DYRK1AWNT1CLK3 | |
| SCHEMBL18451906 | 0.89 | CLK2 (0.57) | CLK2DYRK1AWNT1CLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10206908-B2 | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-02-19 | — | — | US | claimed |
| US-20180214427-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2018-08-02 | — | — | US | claimed |
| WO-2017023984-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC. (US) | 2017-02-09 | — | — | WO | claimed |
| US-10206908-B2 | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180214427-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2018-08-02 | — | — | US | disclosed |
| US-20180214427-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2018-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180214427-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF | WNT3, WNT1, WNT3A | CLK2 2022/4885DYRK1A 802/4885WNT1 2/4885 |
| US-10206908-B2 | 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof | WNT3, WNT1, WNT3A | CLK2 2022/4885DYRK1A 802/4885WNT1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.